3 Big Dividend Stocks Yielding 7%; Analysts Say Buy yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
E-commerce in China is growing at a substantial rate with an increase in internet penetration in the country. Earlier this year, a World Economic Forum report cited data from Statista and eMarketer, stating that more than 50% of global Internet retail sales comprised Chinese e-commerce. According to eMarketer, e-commerce in China is expanding at a faster pace than anywhere else in the world. Using the TipRanks Stock Comparison tool, let us compare two Chinese e-commerce companies, Alibaba, and P
10 Best Upside Stocks to Buy Right Now
As technology-related growth stocks undergo a lean spell after record-shattering gains over the past twelve months, the future outlook of the broader market has become uncertain. This is primarily the result of confusion around new infrastructure plans, which still have to pass Congressional politics before becoming law, and the slow burnout of fiscal and monetary stimulus packages designed to help businesses through the pandemic. In such a scenario, even market experts are finding it hard to predict growth catalysts over the next few months.
Some of this uncertainty is due to the dominance of the large-cap technology stocks on the market that have been responsible for the majority of the overall growth over the past decade. In the first three months of 2021, a whopping 85% of stocks on the S&P 500, more than 20% of which is made up of large-cap tech firms, beat profit expectations of Wall Street analysts. Some of the companies that drove th
Markets
Boston Scientific (BSX)
Oppenheimer analyst Steven Lichtman assigned a Hold rating to Boston Scientific yesterday and set a price target of $47.00. The company’s shares closed last Wednesday at $44.24.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 20.5% and a 59.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Organogenesis Holdings, and Merit Medical Systems.
Boston Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $45.55.
Apellis Pharmaceuticals (APLS)
Oppenheimer analyst Justin Kim assigned a Buy rating to Apellis Pharmaceuticals yesterday and set a price target of $62.00. The company’s shares closed last Wednesday at $45.30.
There’s a lot to be optimistic about in the Consumer Goods sector as 3 analysts just weighed in on Monster Beverage (MNST – Research Report), Mondelez International (MDLZ – Research Report) and Duluth Holdings (DLTH – Research Report) with bullish sentiments.
Monster Beverage (MNST)
Evercore ISI analyst Robert Ottenstein maintained a Buy rating on Monster Beverage yesterday and set a price target of $105.00. The company’s shares closed last Wednesday at $96.47, close to its 52-week high of $99.24.
According to TipRanks.com, Ottenstein is a 3-star analyst with an average return of 3.7% and a 59.0% success rate. Ottenstein covers the Consumer Goods sector, focusing on stocks such as The Estée Lauder Companies, Duckhorn Portfolio, and Colgate-Palmolive.